Plasmacure, a medical technology company dedicated to transforming wound care, has secured $6,000,000 in new funding. This investment marks a significant step for the company as it advances its mission to address the urgent needs of millions of individuals living with hard-to-heal wounds globally.
The company's core innovation is PLASOMA, a patented cold plasma system designed to establish a new standard in the treatment of complex wounds. With aging populations and a growing prevalence of conditions like diabetes driving chronic wounds, existing treatment protocols often face challenges regarding effectiveness and cost. PLASOMA, a CE-marked Class IIb medical device, has demonstrated superior efficacy in clinical trials, showing to be 2.5 times more effective at closing complex wounds than traditional methods.
PLASOMA delivers cold plasma directly to the wound site via disposable pads, integrating easily into existing care workflows with just two minutes per session. The system offers substantial benefits, including the potential to reduce healthcare costs by over 40% and increase clinical staff productivity by more than 50%. It is currently the only cold plasma wound care solution validated through a peer-reviewed randomized controlled trial as both safe and effective for in-clinic and home use.
The newly secured capital is designated to accelerate Plasmacure's strategic growth initiatives. This includes progressing reimbursement pathways in the Netherlands, expanding its commercial presence across the European Union, and preparing for critical market entry into the United States and China. This funding round underscores investor confidence in Plasmacure's innovative approach and its potential to deliver significant clinical and economic value in the global wound care market. The company is poised to further its expansion, aiming to restore patients’ mobility, dignity, and independence through its transformative technology.
